SIO to Exhibit at CPhI
The company will showcase its injectable grade pharmaceutical oils at CPhI Worldwide.
SIO, an ADM company, a manufacturer and supplier of injectable-grade pharmaceutical oils used as APIs or excipients for oil-soluble drugs, will be attending CPhI Worldwide this year, the company said in an August 4, 2016 press announcement. SIO offers a range of purified oils that meet all relevant pharmaceutical regulations and are manufactured according to cGMP standards.
The company’s injection-grade purified pharmaceutical oils, including refined soybean and olive oils, are currently primarily used as large volume emulsions for parenteral nutrition. SIO also has a portfolio of US Pharmacopoeia (USP) and European Pharmacopoeia (EP) grade vegetable oils, including sunflower and rapeseed oil, which can be used as excipients in soft gels and capsules. The company also offers injection-grade purified sesame oil that responds to different formulation needs, such as controlled release. SIO has contract manufacturing capabilities with cGMP production capacity and labs audited by FDA.
Source: SIO
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
